1. 差距分析 Gap Analysis：
1.1. 对甲方现有的研究数据进行彻底审查，与ICH、中国国家药品监督管理局（NMPA）、美国食品药品监督管理局（FDA）、欧洲药品管理局（EMA）和其他相关全球法规的指南进行比对。
Conduct a thorough review of Party A's existing research data against guidelines from ICH, Chinese NMPA, US FDA, EMA, and other pertinent global regulations.
1.2. 辨识出与每个监管框架的不一致之处和不符合的领域。
Identify discrepancies and areas of non-compliance with each regulatory framework.
1.3. 制定全面的计划来解决这些差距，可能涉及到额外的研究、数据收集或对现有流程的调整。
Develop a comprehensive plan to address these gaps, potentially involving additional studies, data collection, or adjustments to existing protocols
2. 研究标准的制定Formulation of Research Standards：
2.1. 制定精确而全面的研究标准，以适应甲方当前注册阶段的需求
Develop precise and comprehensive research standards tailored to Party A's current stage of registration.
2.2. 确保这些标准涵盖了药物开发的所有方面，包括临床前研究、临床试验等。
Address methodologies for evaluating the impact of changes in raw materials, manufacturing processes, testing protocols, formulations, container closures, etc., on product quality, safety, and efficacy.
3. 质量可比性研究策略Analytical Comparability Research Strategy：
3.1. 制定详细的质量可比性研究策略，从IND阶段开始，延伸至BLA提交及后续阶段。Devise a detailed strategy for conducting analytical comparability research, beginning from the IND stage and extending through BLA submission and subsequent phases.
3.2. 解决评估原材料、生产工艺、测试方法、配方、容器封闭等变更对产品质量、安全性和有效性的影响的方法。
Address methodologies for evaluating the impact of changes in raw materials, manufacturing processes, testing protocols, formulations, container closures, etc., on product quality, safety, and efficacy.
4. 风险评估：
4.1. 对原材料、生产工艺、测试方法、配方、容器封闭等方面的任何变更进行全面的风险评估。
Undertake a thorough risk assessment for any modifications to raw materials, manufacturing processes, testing methodologies, formulations, container closures, etc
4.2. 运用诸如故障模式及影响分析（FMEA）等工具，确定潜在风险并优先考虑应对策略。
Employ tools such as Failure Mode and Effects Analysis (FMEA) to identify potential risks and prioritize mitigation strategies
5. CTD格式文件的准备和审查Preparation and Review of CTD-format Documents：
5.1. 准备并严格审查符合监管要求的通用技术文件（CTD）格式的提交文件。
Prepare and meticulously review Common Technical Document (CTD)-format submissions required for regulatory filings
5.2. 确保文件准确、结构良好，并符合监管标准。
Ensure documents are accurate, well-structured, and compliant with regulatory standards
6. 准备CMC会议文件和回复Preparation of CMC Meeting Documents and Responses：
6.1. 准备与监管机构的CMC会议相关的文件，包括会议请求、简报文件和对机构提出的问题的回复。
Prepare documentation for CMC meetings with regulatory agencies, including meeting requests, briefing packages, and responses to agency queries
6.2. 与相关利益相关者密切合作，以应对会议期间提出的问题和关注点。
Collaborate closely with relevant stakeholders to address inquiries and concerns raised during meetings
7. 零缺陷的注册申请Zero-Defect Regulatory Submission：
7.1. 实施严格的审查和质量保证流程，确保所有与药品注册相关的材料零缺陷。Implement rigorous review and quality assurance processes to achieve zero defects in all pharmaceutical registration-related materials
7.2. 建立健全的文件控制和审查机制，以减少错误，并遵守监管要求。Establish robust document control and review mechanisms to minimize errors and uphold compliance with regulatory mandates.